The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60.

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

The agency's website indicates HHS Secretary Robert F. Kennedy Jr. adopted the previous advisory panel's suggestion to expand access on June 25. AP also reports on FDA vaccine chief Vinay Prasad's ...